Guihéneuf Solène

Dr. Guihéneuf Solène


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in Journal of Power Sources
Verified
Journal Article
Closed access
GSGuihéneuf Solène
Guihéneuf Solène
TGT. Godet-Bar
T. Godet-Bar
JFJ.-M. Fontmorin
J.-M. Fontmorin
CJC. Jourdin
C. Jourdin
DFD. Floner
D. Floner
FGF. Geneste
F. Geneste

9 June 2021 in ChemElectroChem
Verified
Journal Article
Open access
PDF file
GSGuihéneuf Solène
Guihéneuf Solène
ALAurore Lê
Aurore Lê
TGThibault Godet‐Bar
Thibault Godet‐Bar
LCLéa Chancelier
Léa Chancelier
JFJean‐Marie Fontmorin
Jean‐Marie Fontmorin
FGFlorence Geneste
Florence Geneste
The performance of a redox compound in redox flow batteries (RFB) highly depends on the electrolytic medium and operating conditions. It is exemplified in this work with the commercially available and relatively low‐cost dye 3,4‐dihydroxy‐9,10‐anthraquinone‐2‐sulfonic acid (ARS), which was used as negolyte in basic medium. At high pH, the ARS behavior revealed interesting features for RFB applications, such as a low half‐wave potential of −0.99 V (vs Ag/AgCl), negatively shifted by phenolate groups, and an improved solubility compared with acidic medium depending on the nature of the cations. For the highly soluble ARS potassium salt (ARSK), a maximum power density of 117 mW cm−2 and a demonstrated energy density of 20 Wh L−1 were obtained with K4[Fe(CN)6] as posolyte. The capacity slightly decreased during cycling, reaching 90 % after 325 cycles. A long cycling of ARS sodium salt (ARSNa) over 11 operating months was demonstrated in this work. A slow chemical degradation was highlighted giving rise to the formation of 3‐hydroxy‐9,10‐anthraquinone‐2‐sulfonic acid (HAQS) as the main degradation product due to hydrodeoxygenation reaction. Interestingly, this compound exhibited high performance in RFB and a good stability with a loss of capacity of 0.29 % per day.

6 October 2011 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
GSGuihéneuf Solène
Guihéneuf Solène
LPLudovic Paquin
Ludovic Paquin
FCFrancois Carreaux
Francois Carreaux
EDEmilie Durieu
Emilie Durieu
LMLAURENT MEIJER
LAURENT MEIJER
Bazureau Jean PierreBazureau Jean Pierre
Bazureau Jean Pierre
Dispacamide A and new analogs of this marine alkaloid were prepared in seven steps with an overall yield ranging from 12 to 33%. The key step of the strategy was a stereocontrolled Knoevenagel condensation under microwave dielectric heating in the last step. In this condensation, the 2-aminoimidazolin-4-one hydrochloride partners 10a–c were synthesized in three steps with good overall yields (33–79%) via the ring closure of N-guanidino acetic acids 9a–c and the aldehydes 5a,b as the two others building-blocks, in 3 steps with 60–66% overall yields. The six synthetic products have been obtained with a Z geometry about their exocyclic bond on the basis of 13C/1H long-range coupling constants using a gHSQMBC experiment.

23 November 2023 in Electrochimica Acta
Verified
Journal Article
Closed access
IOI. Ozouf
I. Ozouf
JFJ.-M. Fontmorin
J.-M. Fontmorin
RLR. Lebeuf
R. Lebeuf
GMG. Mathieu
G. Mathieu
GSGuihéneuf Solène
Guihéneuf Solène
FGFlorence Geneste
Florence Geneste

27 October 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
KBKhadidja Bourahla
Khadidja Bourahla
GSGuihéneuf Solène
Guihéneuf Solène
LELimanton Emmanuelle
Limanton Emmanuelle
LPLudovic Paquin
Ludovic Paquin
RGRémy Le Guével
Rémy Le Guével
Bazureau Jean PierreBazureau Jean Pierre
Bazureau Jean Pierre
Here, we report on the synthesis of libraries of new 5-arylidene-2-thioxo-1,3-thiazolidin-4-ones 3 (twenty-two compounds) and new 2-amino-5-arylidene-1,3-thiazol-4(5H)-ones 5 (twenty-four compounds) with stereo controlled Z-geometry under microwave irradiation. The 46 designed final compounds were tested in order to determine their activity against four representative protein kinases (DYR1A, CK1, CDK5/p25, and GSK3α/β). Among these 1,3-thiazolidin-4-ones, the molecules (5Z) 5-(4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one 3e (IC50 0.028 μM) and (5Z)-5-benzo[1,3]dioxol-5-ylmethylene-2-(pyridin-2-yl)amino-1,3-thiazol-4(5H)-one 5s (IC50 0.033 μM) were identified as lead compounds and as new nanomolar DYRK1A inhibitors. Some of these compounds in the two libraries have been also evaluated for their in vitro inhibition of cell proliferation (Huh7 D12, Caco2, MDA-MB 231, HCT 116, PC3, and NCI-H2 tumor cell lines). These results will enable us to use the 1,3-thiazolidin-4-one core as pharmacophores to develop potent treatment for neurological or oncological disorders in which DYRK1A is fully involved.